Atibuclimab

阿替布利单抗

Report date: 2026/04/24 20:01:59

Base Information

Drug NameAtibuclimab
Drug Alias NameIC-14
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionMonocyte differentiation antigen CD14 inhibitors
TargetsMonocyte differentiation antigen CD14
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Acutely decompensated congestive heart failureST Elevation Myocardial Infarction +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIcos Corporation
China Registration ClassN/A

Develop Information

Active CompaniesImplicit Bioscience LtdVa Office Of Research And DevelopmentImplicit Bioscience Inc
Inactive CompaniesIcos CorporationUniversity Of WashingtonNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsAcutely decompensated congestive heart failureST Elevation Myocardial InfarctionCardiomyopathies +[9] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Motor Neuron DiseaseLung Diseases +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBank